Shire ViroPharma on Monday hammered a Federal Trade Commission antitrust suit over alleged abuse of the US Food and Drug Administration’s citizen petition process to delay generic competition, calling it procedurally improper and an affront to constitutional rights.
US District Judge Richard Andrews in Wilmington, Delaware on Tuesday ruled the FTC had not met a prerequisite for bringing a lawsuit seeking an injunction in the first place by showing that Shire ViroPharma Inc was about to violate a law.
It was unclear if the FTC would seek to revise its lawsuit, which Andrews said he would allow. The FTC and Dublin-based Shire did not immediately respond to requests for comment on Wednesday.
In its lawsuit, the regulator alleged that ViroPharma, which Shire acquired in 2014, had from 2006 to 2012 filed repeated and unsupported filings with the US Food and Drug Administration to slow approval of generic competitors to Vancocin.
The FTC said ViroPharma, which acquired the drug’s rights from Eli Lilly in 2004, began filing petitions with the FDA in 2006 when the agency set a streamlined procedure for proving that generic rivals were the same chemically as Vancocin.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI